Immutep (NASDAQ: IMMP) — Perfil da empresa, notícias e dados financeiros
Immutep is an Australian biotechnology company developing RNA-based immunotherapy treatments for cancer and autoimmune diseases.
Immutep
Immutep (ASX:IMM), (NASDAQ:IMMP) is an Australian biotechnology company at the forefront of developing novel immunotherapy treatments for cancer and autoimmune diseases. Its pivotal project revolves around leveraging LAG-3 (Lymphocyte Activation Gene-3) to harness and amplify the body's immune response to fight disease. Immutep's portfolio includes a range of proprietary product candidates like eftilagimod alpha, a first-in-class antigen-presenting cell (APC) activator currently undergoing numerous clinical trials across various cancer indications. Their mission is to achieve breakthroughs in treatment paradigms and offer new hope to patients suffering from severe medical conditions. Collaborating globally with pharmaceutical companies, Immutep aims to accelerate the development of its therapeutic assets, solidifying its commitment to innovation in healthcare.
Resumo
Operações
Produtos e/ou serviços de Immutep
- Eftilagimod alpha (efti), an immunotherapy for solid tumors, harnessing the power of the patient's own immune system to fight cancer.
- IMP761, a first-in-class agonist antibody targeting LAG-3 for autoimmune diseases, aiming to reduce immune system overactivity.
- In partnership with large pharma companies, developing combinational therapies using their LAG-3 immunotherapy to enhance treatment efficacy and safety.
- A comprehensive range of LAG-3 products for various cancer types and stages, aiming to offer personalized cancer therapy options.
- Broad patent portfolio protecting their LAG-3 technology and immunotherapy approaches, ensuring sustained innovation and market leadership.
- Continual investment in research and development to expand their LAG-3 product pipeline and address unmet medical needs in cancer and autoimmune diseases.
equipe executiva do Immutep
- Marc VoigtCEO, MD, CFO, Chief Business Officer & Executive Director
- Deanne MillerCOO, General Counsel & Joint Company Secretary
- Frederic TriebelChief Scientific Officer & Executive Director
- Christian MuellerChief Development Officer
- Stephan WinckelsChief Medical Officer
- Indira NaiduJoint Company Secretary
Principais indicadores financeiros
Resultados divulgados pela Immutep , em AUD.
- Cap. de mercado
- 24,5 mi
- Receita (TTM)
- 19,9 mi
- P/L
- —
- LPA (diluído, TTM)
- -7.7
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 14,2 mi | -82 mi | -77,6 mi | |
| 5 mi | -126,4 mi | -61,4 mi | |
| 3,8 mi | -88,1 mi | -42,7 mi | |
| 3,5 mi | -77,7 mi | -39,9 mi |